EDIGENE INC.

In News

Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Sep 15, 2021

EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies - BioInformant

BioInformant - Feb 21, 2022

EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0-based in vivo RNA Editing Therapies in NHP Model at the 26th Annual Meeting of ASGCT via Oral Presentation - Business Wire

Business Wire - May 02, 2023

Chinese Biotech Firm EdiGene Nabs $67m From Sequoia, IDG, Others - Caixin Global

Caixin Global - Oct 14, 2020

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy - medicalxpress.com

medicalxpress.com - Sep 08, 2025

Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval - Clinical Trials Arena

Clinical Trials Arena - Jan 17, 2024

Some of the Key Players in Next Generation Genome Editing Market: - Insightace Analytic

Insightace Analytic - Oct 22, 2024

Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Jul 26, 2023

Tackling rare genetic diseases with own genome editing technology | Entrepreneurs 01 - u-tokyo.ac.jp

u-tokyo.ac.jp - Jan 15, 2021

Kodak touts study to lure pharma manufacturing - BioPharma Dive

BioPharma Dive - Mar 01, 2018

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment